A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years
Abroad (travel likely)RecruitingPHASE1
Conditions
KCNT1-Related Epilepsy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Scientia Clinical Research, Sydney, New South Wales, Australia
Contact: Study coordinator (Christopher Argent, MD) · christopher.argent@scientiaclinicalresearch.com.au · (+61) 2 9382 5800Contact: Principal Investigator (Christopher Argent, MD)
Study leads
Medical Director
Study Director
Actio Bioscences, Inc.